The Aroon Indicator for ARTL entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 257 similar instances where the Aroon Indicator formed such a pattern. In 243 of the 257 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARTL as a result. In 87 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARTL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence (MACD) for ARTL just turned positive on September 30, 2026. Looking at past instances where ARTL's MACD turned positive, the stock continued to rise in 43 of 53 cases over the following month. The odds of a continued upward trend are 81%.
Following a +78.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARTL advanced for three days, in 167 of 218 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.280) is normal, around the industry mean (2.973). P/E Ratio (-0.025) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. ARTL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PALI's RSI Oscillator exited the oversold zone, 34 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for PALI just turned positive on October 08, 2026. Looking at past instances where PALI's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where PALI advanced for three days, in 168 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PALI as a result. In 90 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 50-day moving average for PALI moved below the 200-day moving average on October 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PALI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PALI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.932) is normal, around the industry mean (2.973). P/E Ratio (2.077) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. PALI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PALI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ARTL | PALI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 98 | 3 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 53 Fair valued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 96 | 81 | |
P/E GROWTH RATING 1..100 | 97 | 96 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARTL's Valuation (53) in the null industry is in the same range as PALI (78). This means that ARTL’s stock grew similarly to PALI’s over the last 12 months.
ARTL's Profit vs Risk Rating (100) in the null industry is in the same range as PALI (100). This means that ARTL’s stock grew similarly to PALI’s over the last 12 months.
PALI's SMR Rating (98) in the null industry is in the same range as ARTL (100). This means that PALI’s stock grew similarly to ARTL’s over the last 12 months.
PALI's Price Growth Rating (81) in the null industry is in the same range as ARTL (96). This means that PALI’s stock grew similarly to ARTL’s over the last 12 months.
PALI's P/E Growth Rating (96) in the null industry is in the same range as ARTL (97). This means that PALI’s stock grew similarly to ARTL’s over the last 12 months.
| ARTL | PALI | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 87% |
| Stochastic ODDS (%) | N/A | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 89% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 81% | 1 day ago 81% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 88% | 1 day ago 90% |
| Advances ODDS (%) | about 1 month ago 77% | 8 days ago 84% |
| Declines ODDS (%) | 1 day ago 89% | 1 day ago 90% |
| BollingerBands ODDS (%) | N/A | N/A |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARTL’s FA Score shows that 0 FA rating(s) are green while PALI’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARTL’s TA Score shows that 2 TA indicator(s) are bullish while PALI’s TA Score has 4 bullish TA indicator(s).
ARTL (@Biotechnology) experienced а -6.93% price change this week, while PALI (@Biotechnology) price change was -12.34% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
ARTL is expected to report earnings on Nov 11, 2026.
PALI is expected to report earnings on Nov 09, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IGR | 10.70 | 0.04 | +0.38% |
| CBRE Global Real Estate Income Fund | |||
| SJB | 15.49 | -0.03 | -0.16% |
| ProShares Short High Yield (SJB) | |||
| PPA | 154.53 | -1.29 | -0.83% |
| Invesco Aerospace & Defense ETF (PPA) | |||
| PRCS | 28.93 | -0.37 | -1.25% |
| Parnassus Core Select ETF | |||
| TFGZ | 34.06 | -1.32 | -3.74% |
| Thornburg Focus Growth Fund ETF (TFGZ) | |||